European NGOs in the reform of drugs in the EU

Three major volunteers pointed out this week Your concern that the best drugs are trying to influence In the reforms The EU Forcing the European Commission, which includes new concessions to support innovations amid growing world business tensions.

The European Cancer League Association (ECL), the European Consumer Organization (PEC) and the International Mutual Association (AIM) warned the social administrator in a joint statement. An increase in innovative drugs Many patients who make health inequalities worse throughout Europe cannot reach.

Organizations also asked for governments Give preference to patients and consumers Guarantee affordable access to safe and effective drugs. Since the Commission provided Plan for Drug Reform in May 2023Debates have advanced in the European Parliament, but they have not advanced to the EU Council.

The EU administrator said it is still Confidence in the possibility of achieving a positive decision Through negotiations with legislators. Representatives of the EU member states are expected to meet again next week.

EU diplomats approached last Monday, according to the minutes of the ‘Euronaws’ meeting SafetyParallel trade and novelty, but not investigating the pin problem of regulatory security. After a meeting with the Chairman of the Commission, the CEO of the pharmaceutical department reiterated their demand for strengthening the safety of intellectual assets.

Significant savings for European health organizations

Regulatory Data Protection Periods prevent the use of data provided by competitors Prove that new drugs are safe and effectiveIt helps to create an inexpensive common or piosimillar equal.

For their part, civil society groups argue Reduction in the period of basic data safety Regulatory – currently set in eight years – allow the preceding entry of common and biosymillar in the market. They argue that this change can save European health systems About 1,130 million euros per year.

“Treatment of cancer Impossible without accessing drugs And controlly maintenance. The central purpose of EU drug reform must be clear: to ensure that all cancer patients can be accessed when they are so much needed, “Toma Migalasite, who is responsible for ECL policies, added.

However, pharmaceutical companies They press to achieve the most favorable conditions. Not only because of your demands concern A drug trade war with AmericaBut for the changes in the US national policy.

Is there a price increase in Europe?

If the prices of pharmaceuticals in the European Union are still lower, pharmaceutical companies are more likely to fear that May affect drug pricing policies In the United States, especially in the midst of debates under the Trump administration, the prices of US drugs are compared to the prices of other developed countries.

Companies are concerned Lower European prices cause downward pressure Prices about us, which will lead them to the magazine Prices are increased in Europe.

Large companies such as French Sanoffi and Switzerland are pressed by a joint letter, arguing that Strictly price controls in Europe They are less attractive to the European Union, where they are significantly permitted by more drug prices compared to the US.